News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
345 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17894)
Month
January (4450)
February (4428)
March (5683)
April (4545)
May (5703)
June (4805)
July (3912)
August (4762)
September (4260)
October (3860)
November (4837)
December (2683)
Day
1 (345)
2 (262)
3 (257)
4 (129)
5 (4)
6 (21)
7 (185)
8 (394)
9 (260)
10 (315)
11 (117)
13 (9)
14 (254)
15 (253)
16 (249)
17 (224)
18 (72)
19 (3)
20 (23)
21 (246)
22 (281)
23 (295)
24 (291)
25 (114)
26 (10)
27 (6)
28 (274)
29 (262)
30 (229)
31 (299)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Biotech Bay
Augmedix to Participate at the 2022 JMP Securities Technology Conference
Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco.
March 1, 2022
·
1 min read
Bio NC
Humacyte to Present at Upcoming Investor Conferences in March 2022
Humacyte, Inc. announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.
March 1, 2022
·
1 min read
Policy
U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
Cabaletta Bio, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation for MuSK-CAART, or muscle-specific kinase chimeric autoantibody receptor T cells, to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis.
March 1, 2022
·
7 min read
Genetown
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
Candel Therapeutics, Inc. (Nasdaq: CADL) (the “Company” or “Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has entered into a loan and security agreement with Silicon Valley Bank for $25 million, $20 million of which will be available immediately.
March 1, 2022
·
4 min read
BioCapital
Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be participating in upcoming investor and scientific conferences.
March 1, 2022
·
2 min read
Business
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the appointment of James Hassard as chief commercial officer.
March 1, 2022
·
6 min read
Biotech Beach
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
Organovo Holdings, Inc., and BICO announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting.
March 1, 2022
·
3 min read
Business
F-star Therapeutics Appoints James Sandy as Chief Development Officer
F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today.
March 1, 2022
·
6 min read
Business
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune response to cancers and infections, provided a corporate update and reported financial results for the fourth quarter and full year 2021.
March 1, 2022
·
10 min read
Biotech Bay
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to expand into Canada.
March 1, 2022
·
4 min read
Previous
20 of 35
Next